Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S's Partner Merck & Co Inc Submits BLA for Marketing Authorization of Grass AIT to FDA


Friday, 1 Feb 2013 07:00am EST 

Alk Abello A/S announced that its partner Merck & Co Inc has submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for a marketing authorization for grass allergy immunotherapy tablet (AIT) – a disease-modifying AIT against grass pollen allergy. The product is marketed as GRAZAX in Europe. The partnership with Merck covers the develop­ment, registration and commercialization of a portfolio of AITs in North America. The application to the FDA is based on results from a clinical development program. Data from the clinical trials have demonstrated that treatment with grass AIT reduces patients’ allergy symptoms and their need for symptom-relieving medication and provides a sustained long-term effect after completion of treatment. 

Company Quote

56.683
1.173 +2.11%
23 Oct 2014